



**HAL**  
open science

## **IRE1 endoribonuclease signaling promotes myeloid cell infiltration in glioblastoma**

Joanna Obacz, Jérôme Archambeau, Elodie Lafont, Manon Nivet, Sophie Martin, Marc Aubry, Konstantinos Voutetakis, Raphaël Pineau, Rachel Boniface, Daria Sicari, et al.

► **To cite this version:**

Joanna Obacz, Jérôme Archambeau, Elodie Lafont, Manon Nivet, Sophie Martin, et al.. IRE1 endoribonuclease signaling promotes myeloid cell infiltration in glioblastoma. *Neuro-Oncology*, 2023, *Neuro-Oncology*, 10.1093/neuonc/noad256 . hal-04388457

**HAL Id: hal-04388457**

**<https://hal.science/hal-04388457v1>**

Submitted on 29 Feb 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

1 **IRE1 endoribonuclease signaling promotes myeloid cell infiltration in**  
2 **glioblastoma**

3 Joanna Obacz<sup>1,2</sup>, Jérôme Archambeau<sup>1,2</sup>, Elodie Lafont<sup>1,2</sup>, Manon Nivet<sup>1,2</sup>, Sophie Martin<sup>1,2</sup>,  
4 Marc Aubry<sup>1</sup>, Konstantinos Voutetakis<sup>3,4</sup>, Raphael Pineau<sup>1,2</sup>, Rachel Boniface<sup>1</sup>, Daria Sicari<sup>1,2</sup>,  
5 Diana Pelizzari-Raymundo<sup>1,2</sup>, Gevorg Ghukasyan<sup>5</sup>, Eoghan McGrath<sup>1,2</sup>, Efstathios-Iason  
6 Vlachavas<sup>6</sup>, Matthieu Le Gallo<sup>1,2</sup>, Pierre Jean Le Reste<sup>1,2,7</sup>, Kim Barroso<sup>8,9,10,11</sup>, Tanya  
7 Fainsod-Levi<sup>12</sup>, Akram Obiedat<sup>13</sup>, Zvi Granot<sup>12</sup>, Boaz Tirosh<sup>13</sup>, Juhi Samal<sup>14</sup>, Abhay Pandit<sup>14</sup>,  
8 Luc Négroni<sup>8,9,10,11</sup>, Nicolas Soriano<sup>1,15</sup>, Annabelle Monnier<sup>1</sup>, Jean Mosser<sup>1</sup>, Aristotelis  
9 Chatziioannou<sup>3,6</sup>, Véronique Quillien<sup>1,2</sup>, Eric Chevet<sup>1,2</sup> and Tony Avril<sup>1,2</sup>

10

11 <sup>1</sup>INSERM U1242, Rennes, France. <sup>2</sup>Centre Eugène Marquis, Rennes. <sup>3</sup>ICB, NHRF, Athens,  
12 Greece. <sup>4</sup>Department of Biochemistry and Biotechnology, Larissa, Greece. <sup>5</sup>Biosit H2P2,  
13 Rennes. <sup>6</sup>e-NIOS PC, Kallithea-Athens. <sup>7</sup>Hospital of St Malo, France. <sup>8</sup>IGBMC, Illkirch, France.  
14 <sup>9</sup>CNRS UMR7104, Illkirch. <sup>10</sup>INSERM U1258, Illkirch. <sup>11</sup>Université de Strasbourg, France.  
15 <sup>12</sup>Department of Developmental Biology and Cancer Research, Hebrew University of  
16 Jerusalem, Israel. <sup>13</sup>IDR, Hebrew University of Jerusalem. <sup>14</sup>CÚRAM, Ireland. <sup>15</sup>CNRS  
17 UMR6290, Rennes.

18

19 **Corresponding author:** Tony Avril, Centre Eugène Marquis, Avenue de la bataille Flandres  
20 Dunkerque, 35042 RENNES. Email: [t.avril@rennes.unicancer.fr](mailto:t.avril@rennes.unicancer.fr)

21

22 **Competing Interests**

23 EC is founder of Thabor Therapeutics (www.thabor-tx.com). The other authors declare no  
24 conflicting interests.

25

1 **Abstract**

2 *Background:* Intrinsic or environmental stresses trigger the accumulation of improperly folded  
3 proteins in the endoplasmic reticulum (ER), leading to ER stress. To cope with this, cells have  
4 evolved an adaptive mechanism named the unfolded protein response (UPR) which is  
5 hijacked by tumor cells to develop malignant features. Glioblastoma (GB), the most aggressive  
6 and lethal primary brain tumor, relies on UPR to sustain growth. We recently showed that IRE1  
7 alpha (referred to IRE1 hereafter), one of the UPR transducers, promotes GB invasion,  
8 angiogenesis and infiltration by macrophage. Hence, high tumor IRE1 activity in tumor cells  
9 predicts worse outcome. Herein, we characterized the IRE1-dependent signaling that shapes  
10 the immune microenvironment towards monocytes/macrophages and neutrophils. *Methods:*  
11 We used human and mouse cellular models in which IRE1 was genetically or  
12 pharmacologically invalidated and which were tested in vivo. Publicly available datasets from  
13 GB patients were also analyzed to confirm our findings. *Results:* We showed that IRE1  
14 signaling, through both the transcription factor XBP1s and the regulated IRE1-dependent  
15 decay (RIDD) controls the expression of the ubiquitin-conjugating E2 enzyme UBE2D3. In  
16 turn, UBE2D3 activates the NF $\kappa$ B pathway, ensuing chemokine production and myeloid  
17 infiltration in tumors. *Conclusion:* Our work identifies a novel IRE1/UBE2D3 pro-inflammatory  
18 axis that plays an instrumental role in GB immune regulation.

19

20 **Key words:** glioblastoma, ER stress, IRE1, chemokines, inflammation.

21

22 **Key points:**

- 23 - Glioblastoma IRE1 activity promotes myeloid recruitment via chemokine expression  
24 - UBE2D3, a novel component of IRE1/XBP1s/RIDD signaling, controls NF $\kappa$ B activation  
25 - UBE2D3 controls glioblastoma myeloid cell infiltration *in vivo*

26


27

1 **Importance of the Study**

2 Glioblastoma aggressiveness partly owes its dismal prognosis to the presence of a tumor  
3 supportive microenvironment. Indeed, stromal cells including microglial cells and  
4 macrophages promote GB growth. This study stems from our initial observation that the  
5 activation of the ER stress sensor IRE1 in GB cells controls the recruitment of host's immune  
6 cells (macrophages and microglial cells mainly). However, the precise mechanisms by which  
7 IRE1 exerts this function remain unclear. Herein, we dissected the pathways responsible for  
8 these proinflammatory signals. We found that UBE2D3, a novel target of IRE1/XBP1s/RIDD  
9 signaling, controls NFκB activation in GB cells and the subsequent myeloid infiltration in vivo  
10 via chemokine expression. Targeting IRE1 signaling might impede GB aggressiveness, not  
11 only by reducing tumor cell invasion and angiogenesis, but also by neutralizing the pro-tumoral  
12 inflammation. This study opens a new avenue for therapeutic approaches to improve the  
13 efficacy of current treatments.

14

15 **Graphical abstract**



16  
17

## 1 **Introduction**

2 Perturbation of ER protein homeostasis is one of the hallmarks of highly proliferative and/or  
3 secretory cells. Moreover, many intrinsic and environmental conditions, such as low oxygen  
4 levels, acidification or nutrients shortage also increase the risk of misfolded proteins  
5 accumulation in the ER lumen, leading to ER stress. To cope with the latter, cells use the UPR  
6 which is transduced by the ER transmembrane proteins PERK, ATF6 and the most conserved  
7 UPR sensor IRE1 alpha (referred to as IRE1 hereafter). The UPR restores ER homeostasis  
8 or induce apoptosis when stress cannot be resolved<sup>1</sup>. Once activated, IRE1, which harbors  
9 cytosolic kinase and ribonuclease (RNase) activities, dimerizes/oligomerizes, thus inducing  
10 the activation of JNK1, XBP1 mRNA splicing (XBP1s) and Regulated IRE1-dependent decay  
11 (RIDD) of RNA<sup>2</sup>. XBP1s activates the transcription of genes involved in protein glycosylation,  
12 ER-associated degradation, protein folding, and lipid synthesis. RIDD also controls cell fate  
13 under ER stress<sup>3</sup>. The UPR has emerged as an adaptive mechanism supporting tumor  
14 progression and resistance to treatment by impacting almost all cancer hallmarks<sup>4</sup>. Mounting  
15 evidence also suggests that the UPR shapes the tumor microenvironment by regulating  
16 angiogenesis, inflammation and immune response<sup>5,6</sup>.

17         The consequences of UPR signaling have been studied in various cancers such as  
18 breast, liver, lung, prostate, pancreas cancers and in GB, the most lethal and aggressive  
19 primary brain tumors. IRE1 contributes to GB development by regulating tumor growth,  
20 invasion and vascularization<sup>7,8</sup>. Loss of IRE1 signaling also results in decreased expression  
21 of proangiogenic and proinflammatory VEGFA, IL1 $\beta$ , IL6, and IL8 in GB cells<sup>8</sup>. Importantly,  
22 we have shown a pivotal role of IRE1 in the immune remodeling of GB stroma, which mostly  
23 depends on XBP1s<sup>9,10</sup>. However, the precise IRE1-dependent mechanisms by which pro-  
24 tumoral inflammation/immune responses are regulated in GB remain elusive. IRE1 signaling  
25 induces the expression of proinflammatory chemokines in various models through XBP1s and  
26 JNK-dependent pathways or through GSK3 $\beta$  induction. IRE1 also interacts with TRAF2,  
27 recruiting I $\kappa$ B kinases (IKK), to promote the degradation of I $\kappa$ B thereby enabling NF $\kappa$ B nuclear

1 translocation<sup>11</sup>. Since brain tumors are infiltrated by a large number of immune cells, which  
2 modulate GB aggressiveness and response to treatment, we aimed here to investigate the  
3 molecular mechanisms by which IRE1 controls GB tumor infiltration by immune/inflammatory  
4 cells. We showed that IRE1 governs myeloid cell recruitment to GB. This involves a novel  
5 IRE1/UBE2D3/NF $\kappa$ B signaling axis, thereby leading to proinflammatory chemokine production  
6 and the subsequent recruitment of immune/inflammatory cells to the tumor site.

7

1 **Materials and Methods**

2 **Antibodies and other reagents** – Primary antibodies are listed in **Table S1**. Secondary  
3 antibodies used were horseradish peroxidase conjugated polyclonal goat anti-rabbit IgG, goat  
4 anti-mouse IgG and rabbit anti-goat IgG (all from Dako). Unless specified, all other reagents  
5 were from Sigma Aldrich.

6 **Cell culture and treatments** – The U87, U87 IRE1.NCK DN cells (referred to as U87 DN),  
7 U251 and GL261 lines (all from ATCC) were grown in DMEM medium (Invitrogen)  
8 supplemented with 10% fetal bovine serum (FBS) (Lonza) in a 5% CO<sub>2</sub> humidified atmosphere  
9 at 37°C. Primary GB lines were previously described<sup>10,12</sup>.

10 **Generation of stable cell lines** – For stable overexpression of UBE2D3, RADH87 and GL261  
11 cells were transfected with 3µg of pCMV3-UBE2D3-Flag plasmid using Lipofectamine LTX  
12 and 2000, respectively (ThermoFisher), following the manufacturer's protocol. For stable  
13 ube2d3-downexpression, GL261 cells were transfected with 1µg of pRS shRN-ube2d3.  
14 Transfections of GB lines with IRE1 WT and Q780\* constructs<sup>10</sup> were performed using  
15 Lipofectamine LTX (ThermoFisher), according to the manufacturer's instructions. IRE1 WT  
16 and Q780\* overexpressing cells were selected using puromycin (ThermoFisher).

17 **Quantitative real-time PCR** – Total RNA was extracted using the TRIzol reagent (Invitrogen).  
18 RNAs were reverse-transcribed with Maxima Reverse Transcriptase (ThermoFisher),  
19 according to the manufacturer's protocol. qPCR was performed with a QuantStudio™ 5 Real-  
20 Time PCR System and the PowerUp™ SYBR Green Master Mix (ThermoFisher). Experiments  
21 were performed at least in triplicate for each data point. Each sample was normalized based  
22 on the expression of the GAPDH or ACTB gene using the 2<sup>ΔΔCT</sup>-method. Primers pairs are  
23 listed in **Table S2**.

24 **Gel shift assay** – Gel shift assay was performed using the LightShift Chemiluminescent  
25 EMSA Kit (ThermoFisher) according to the manufacturer's instructions. Biotin end-labeled  
26 probes were prepared by PCR using 5' Biotin labeled primers (**Table S3**).

1 **Flow cytometry analyses** – Cells were washed in PBS 2% FBS and incubated with saturating  
2 concentrations of human immunoglobulins and fluorescent-labelled primary antibodies as  
3 indicated for 30 minutes at 4°C. Cells were then washed with PBS 2% FBS and analyzed  
4 using a FACSCanto and Novocyte flow cytometers (BD Biosciences and Acea Biosciences).

5 **Myeloid chemoattraction assay** – Myeloid cells were washed in DMEM and placed in 3  $\mu$ m  
6 Boyden chambers (Merck Millipore), at  $0.5 \times 10^5$  cells/chamber in 200  $\mu$ L DMEM. Chambers  
7 were simultaneously placed in 500  $\mu$ L of either control DMEM or tumor cell-conditioned media,  
8 and incubated for 2 hours (for PMN) or 16 hours (for Mo) at 37°C. Migrated myeloid cells  
9 (under the Boyden chambers) were analyzed by flow cytometry.

10 Detailed methods are in the Supplemental Materials and Methods. This study does not include  
11 any data deposited in external repositories.

12



## 1 Results

### 2 Myeloid cells are recruited to GB in an IRE1-dependent manner

3 We previously demonstrated that IRE1 activity in GB cells controls the recruitment of  
4 inflammatory cells such as macrophages and microglial cells<sup>10</sup>. Herein, we tested whether this  
5 also applied to other immune cells from the myeloid or lymphoid lineages. To this end, we first  
6 investigated whether immune gene signatures were associated with IRE1 activity<sup>10</sup> using the  
7 TCGA GB datasets. These immune gene signatures characterize microglia/macrophages  
8 (MM) (i.e. blood monocytes-derived macrophages (MDM), microglia cells (MG)<sup>13-15</sup>);  
9 polymorphonuclear neutrophils (PMN) and T cells (T). Myeloid MM (indifferently MDM and  
10 MG cells) and PMN cells were strongly linked to the high IRE1 activity gene signature whereas  
11 T cells were not (**Fig.1A, S1A-B**). Using flow cytometry, we confirmed the presence of both  
12 myeloid populations in freshly dissociated samples from an in-house GB cohort (n=82) by  
13 quantifying expression of specific markers for each cell type (**Fig.1B-C, S1C-F**). Immune cell  
14 infiltration was higher in GB compared to grade II and III gliomas (**Fig.1B**), in particular CD45+  
15 cells expressing MM and PMN markers (**Fig.1C, S1F**). MM constituted a majority of GB  
16 infiltrates<sup>16</sup>, PMN were found in approximately 20% of the specimens, and T cell infiltration  
17 was rare (below 10%) (**Fig.1C**). Remarkably, infiltration of immune cells was higher in tumors  
18 with high IRE1 activity (**Fig.1D**), including CD11b positive cells expressing MM markers CD14,  
19 CD64 (specific for MDM/MMG) and CD163 (specific for MDM); and PMN markers CD15 and  
20 CD66b (**Fig.1E**). Again, T cell recruitment was not dependent on IRE1 activity (**Fig.1E**). This  
21 suggests that IRE1 signaling could contribute to myeloid attraction, which in turn may promote  
22 tumor aggressiveness. To test this hypothesis, monocytes and neutrophils attraction was  
23 assessed *in vitro*. Myeloid cells from healthy donors' blood, including monocytes (Mo) and  
24 PMN, were characterized based on the expression of CD14, CD15, CD66b and CD16  
25 (**Fig.S1G**). In addition, we generated the RADH87 line stably overexpressing wild-type (WT)  
26 IRE1 or the truncated IRE1 variant, Q780\* which is devoid of its kinase and RNase domains  
27 (**Fig.S1H-I**). The latter mutation attenuated IRE1 signaling (**Fig.S1J**), therefore resembling the  
28 characteristics of U87 DN cells which are deficient for IRE1 activation<sup>10</sup>. As shown in **Fig.1F-**

1 **G**, conditioned media derived from U87 DN and RADH87 Q780\* did not recapitulate the  
2 migratory abilities of Mo and PMN in the Boyden chamber assay, when compared to  
3 conditioned media from parental U87 and RADH87 cells or RADH87 IRE1 WT cells. Thus,  
4 IRE1 activation in GB cells promotes PMN and Mo chemotaxis. Lastly, we evaluated the role  
5 of IRE1 activity in myeloid recruitment *in vivo* using two syngeneic GB mouse models. As  
6 such, mice were orthotopically injected with GL261 cells. Fourteen days later, mice underwent  
7 surgical tumor removal, followed by insertion of either an empty gel implant (CTR) or an  
8 implant containing the IRE1 RNase inhibitor, MKC8866 (MKC)<sup>5,9</sup>. Tumor size and overall  
9 survival obtained in both CTR and MKC groups were similar<sup>9</sup>. We showed that  
10 pharmacological abrogation of IRE1 activity by MKC8866 significantly reduced PMN infiltration  
11 in the recurring tumors mainly at the tumor core (**Fig.1H-I**) and led to increased MM  
12 recruitment at the tumor periphery (**Fig.S1K**). Additionally, mice were orthotopically injected  
13 with CT2A cells and treated with a novel IRE1 inhibitor B2-1, derived from the IRE1 inhibitor  
14 Z4P<sup>17</sup>, that crosses the brain blood barrier<sup>18</sup>. Again, groups of CTR and B2-1 treated mice  
15 displayed similar tumor sizes and overall survival. However, the massive MM recruitment  
16 found in the CTR group was reduced upon IRE1 inhibition, similar to what was observed with  
17 PMN (**Fig.1H-I**). Overall, our results demonstrate that GB are infiltrated by myeloid cells, a  
18 phenomenon partly mediated by IRE1 signaling in tumor cells.

19

## 20 **IRE1 activity regulates expression of myeloid-attracting chemokines**

21 We next hypothesized that IRE1 activity in tumor cells controls expression of myeloid-  
22 attracting chemokines. The latter have been described in different cancer models and include  
23 CXCL1, CXCL2, CXCL5, CXCL7, IL6, and IL8 for PMN<sup>19</sup> and CCL2, CCL3, CCL5, CCL8, IL6  
24 and IL8 for MM<sup>20</sup>. Using the TCGA dataset, we demonstrated that tumors with high IRE1  
25 activity expressed high mRNA levels of the aforementioned cytokines/chemokines (**Fig.2A**).  
26 IRE1-dependent modulation of CXCL2, CXCL5, IL6 and IL8 was expected as these are part  
27 of the IRE1 activity signature<sup>10</sup>. Increased mRNA expression of these cytokines/chemokines  
28 in tumors correlated with higher expression of CD14 and CD15/CD16, markers for MM and

1 PMN, respectively (**Fig.2B, S2A**). To test whether those soluble factors promoted myeloid  
2 recruitment to GB, freshly isolated Mo and PMN were exposed to media conditioned by  
3 various GB lines, which resulted in significant induction of myeloid migration (**Fig.2C**). Using  
4 ELISA, we found that myeloid chemoattraction was correlated with elevated levels of CXCL2,  
5 IL6 and IL8 in these conditioned media (**Fig.2C**). PMN (but not Mo) attraction was partially  
6 blocked by SB225002, an antagonist of the IL8 receptor CXCR2 (**Fig.2D**). In line with our  
7 previous work<sup>8</sup>, we showed that expression of myeloid-attracting chemokines depended on  
8 IRE1 activity. Indeed, expression of CXCL2, IL6 and IL8 mRNA but not CCL2 was dramatically  
9 reduced in U87 DN and RADH87 Q780\* cells when compared to control or IRE1 WT-  
10 overexpressing cells (**Fig.2E-F**). Intriguingly, none of these chemokines/cytokines are known  
11 direct targets of XBP1s<sup>21</sup>, suggesting an indirect contribution of XBP1s to this process. These  
12 findings indicate that IRE1 signaling, possibly through an indirect role of XBP1s, promotes the  
13 expression of chemokines involved in myeloid infiltration of tumors.

14

### 15 **IRE1/XBP1s/RIDD control myeloid infiltration to GB via NF $\kappa$ B and UBE2D3**

16 Since the expression of the aforementioned proinflammatory chemokines is controlled by  
17 NF $\kappa$ B<sup>22</sup>, we tested whether a NF $\kappa$ B signaling gene signature was associated with IRE1,  
18 XBP1s and RIDD signatures previously established<sup>10</sup> using the TCGA data. This revealed that  
19 both XBP1s and RIDD signaling were oppositely associated with elevated NF $\kappa$ B activation  
20 (**Fig.3A**). We also analyzed NF $\kappa$ B activation in IRE1 signaling deficient U87 DN cells  
21 compared to parental cells. The expression and phosphorylation of NF $\kappa$ B was lower in U87  
22 DN cells compared to control (**Fig.S2B**), demonstrating a functional relationship between IRE1  
23 signaling and NF $\kappa$ B. Next, we postulated that IRE1 through both XBP1s and RIDD could  
24 oppositely regulate molecular actors that control NF $\kappa$ B activation. We thus compared lists  
25 comprising XBP1s direct targets identified using ChIPseq<sup>21</sup> with RIDD targets described in<sup>10</sup>;  
26 and identified 28 genes (**Fig.3B**). Among them, expression of seven correlated (either  
27 positively or negatively) with the IRE1 signature and only three with XBP1s and RIDD

1 signatures in GB samples (**Fig.3B**). Additionally, expression of only one of them, namely the  
2 E2 ubiquitin-conjugating enzyme UBE2D3, showed a marked positive correlation with NF $\kappa$ B  
3 activation (**Fig.3C**). Using TCGA transcriptome and RNAseq datasets, we showed that  
4 UBE2D3 mRNA expression was significantly higher in tumors with high IRE1 and XBP1s  
5 activities (**Fig.3D**) and in tumors expressing XBP1s mRNA (**Fig.3E**); but remained unaffected  
6 in tumors with high RIDD activity (**Fig.3D**). We then focused our attention on UBE2D3 as it  
7 also contributes to I $\kappa$ B degradation, and thus NF $\kappa$ B activation<sup>23,24</sup>. Intriguingly, we did not  
8 observe any effect on UBE2D3 mRNA or protein expression upon transient IRE1 inhibition  
9 using MKC8866 (**Fig.S2C-D**) or siRNA targeting either IRE1 (**Fig.S2E**) or XBP1 (**Fig.3F-G**,  
10 **S2F-H**). In addition, no effect was observed when the IRE1 activator IXA4 was used (**Fig.S2C-**  
11 **D**). However, UBE2D3 expression was reduced when IRE1 activity was stably attenuated in  
12 dominant negative U87 and RADH87 cells (**Fig.3H**). The effect was reversed by  
13 overexpressing XBP1s ectopically in these IRE1-defective cells (**Fig.3I**). This indicates that  
14 XBP1s could act as a transcriptional activator of UBE2D3 expression. Using the MatInspector  
15 and TFBIND tools, we found multiple potential XBP1s binding sites within the human and  
16 mouse UBE2D3 promoter region (**Fig.3J, S2I**). Gel shift assays revealed two sites for XBP1s  
17 binding on the human (sites *h1* and *h3*, **Fig.3K-L**) and one on the mouse (site *m1*, **Fig.S2J**)  
18 UBE2D3 promoter regions. Remarkably, multiple bands presented slower mobilities  
19 corresponding to higher molecular weight entities, suggesting that XBP1s could be part of  
20 larger complexes. Both human and mouse sites on the UBE2D3 promoter are flanked by other  
21 transcription factors binding sites, some of which are known to associate with XBP1s (data  
22 not shown). These results suggest that UBE2D3 expression could be regulated by XBP1s. At  
23 this stage however, an indirect control of XBP1s on UBE2D3 transcription cannot be excluded  
24 and further investigations are needed.

25         Conversely, UBE2D3 mRNA expression was decreased upon ER stress and this was  
26 significantly reduced upon treatment with MKC8866 (**Fig.4A**), suggesting that UBE2D3 is also  
27 targeted by RIDD upon ER stress. UBE2D3 functions together with E3 ligases including

1 SYVN1<sup>25</sup>. Since SYVN1 was previously demonstrated to contribute to IRE1 stability<sup>26</sup>, we  
2 asked whether UBE2D3 also contributes to IRE1 expression regulation. As such modulation  
3 of UBE2D3 expression using either ectopic overexpression or siRNA silencing respectively  
4 led to reduced or increased IRE1 expression, independent of ER stress (**Fig.4B**).  
5 Furthermore, SYVN1 contributed to UBE2D3-dependent IRE1 degradation as shown using  
6 SYVN1 siRNA silencing in UBE2D3-overexpressing cells (**Fig.4C**). Notably, in contrast to  
7 UBE2D3, SYVN1 expression was neither modulated by IRE1 activity (**Fig.S2K**) nor  
8 associated with NF $\kappa$ B signaling pathway (**Fig.S2L**). Taken together, these results suggest that  
9 (i) in a basal/chronic ER stress situation, a prolonged inhibition of IRE1 activity (which is  
10 achieved by stable IRE1 DN overexpression, but not by a transient knockdown of IRE1/XBP1  
11 or a short-term MKC treatment *in vitro*) is required to counteract IRE1-XBP1s-driven  
12 expression of UBE2D3 and that (ii) upon acute ER stress induction, transient IRE1 inhibition  
13 by MKC is sufficient to repress IRE1-mediated (RIDD-dependent) decrease of UBE2D3  
14 expression. Thus, IRE1 via XBP1s and RIDD tightly controls UBE2D3 expression which, in  
15 turn, regulates IRE1 stability through SYVN1 as a feed-back mechanism (**Fig.4D**).

16 Next, both XBP1s and RIDD signatures previously established<sup>10</sup> were applied to the  
17 GB TCGA datasets to test whether these IRE1 signaling branches were associated with  
18 immune cell signatures. Importantly, the XBP1s signature was strongly linked to MM (including  
19 MG and MDM), PMN but not T immune signatures (**Fig.S3A**). In contrast, only the PMN  
20 signature was associated with the RIDD branch (**Fig.S3A**). Furthermore, amongst the IRE1  
21 high/XBP1s high group, RIDD activity had no effect on myeloid recruitment whereas PMN  
22 were positively regulated by XBP1s activity in the IRE1 high/RIDD high group (**Fig.S3B**).  
23 Taken together, these data suggest that XBP1s is the main responsible of IRE1-controlled GB  
24 infiltration by myeloid cells.

25

26 **UBE2D3 cooperates with MIB1 to trigger NF $\kappa$ B proinflammatory response**

1 To investigate how UBE2D3 modulates NF $\kappa$ B activation, we evaluated the impact of UBE2D3  
2 overexpression in GB lines on the NF $\kappa$ B regulator I $\kappa$ B and on the subsequent activation of the  
3 NF $\kappa$ B pathway. UBE2D3 overexpression led to I $\kappa$ B degradation and concomitant increased  
4 phosphorylation of NF $\kappa$ B (**Fig.5A, S4A-D**). To identify the putative E3 ligase(s) involved in I $\kappa$ B  
5 degradation and/or NF $\kappa$ B activation as well as to investigate the global effect of UBE2D3 on  
6 protein ubiquitination in GB, we carried out a label-free quantitative MS/MS analysis using  
7 cells stably overexpressing UBE2D3 (**Fig.S5**). Details of this analysis are in the Supplemental  
8 Results. Among proteins modulated by UBE2D3 expression, we identified the E3 ligase MIB1,  
9 a known regulator of NF $\kappa$ B activation<sup>27</sup> and interactor with UBE2D3<sup>28</sup>. Therefore, we  
10 investigated whether MIB1 cooperates with UBE2D3 to trigger the degradation of I $\kappa$ B. We  
11 found that MIB1 silencing partially prevented the UBE2D3-mediated degradation of I $\kappa$ B protein  
12 (**Fig.5B, S6A-B**). However, MIB1 also controlled UBE2D3 directly as MIB1 silencing led to  
13 increased expression of both UBE2D3 mRNA (**Fig.S6C**) and protein (**Fig.5B, S6A**),  
14 suggesting a complex interaction between these molecules. Overall, these results suggest the  
15 existence of a signaling axis involving UBE2D3 and MIB1 that is sufficient to trigger the  
16 activation of NF $\kappa$ B-dependent proinflammatory response in GB (**Fig.5G**), and which needs to  
17 be further analyzed.

18

### 19 **IRE1/UBE2D3 control myeloid recruitment to GB through NF $\kappa$ B proinflammatory** 20 **response**

21 To further investigate the role of UBE2D3 in myeloid mediated immunity, we stratified the  
22 TCGA GB cohort according to UBE2D3 mRNA levels and tested mRNA expression of the  
23 main myeloid-attracting cytokines/chemokines. We demonstrated that tumors with high  
24 UBE2D3 expression levels also expressed significantly higher levels of CCL2, CXCL2, IL6  
25 and IL8 mRNA (**Fig.5C**). Next, we evaluated the expression of myeloid-attracting chemokines  
26 by RT-qPCR in UBE2D3-overexpressing cells. This showed that CCL2, CXCL2, IL6 and IL8  
27 expression was markedly induced upon UBE2D3 overexpression (**Fig.5D**). In addition,

1 treatment of U87 cells with the NF $\kappa$ B inhibitor JSH-23, which prevents NF $\kappa$ B activity, blunted  
2 the observed UBE2D3-dependent increase in CCL2 CXCL2, IL6 and IL8 mRNA expression  
3 (**Fig.5E**). We next found that MIB1 silencing partially prevented the UBE2D3-mediated  
4 upregulation of CCL2, CXCL2, IL6 and IL8 in UBE2D3-overexpressing cells compared to  
5 control (**Fig.S6D**). Finally, we analyzed Mo and PMN attraction properties of conditioned  
6 media from GB cells modified for UBE2D3 expression. We confirmed that media conditioned  
7 by UBE2D3-overexpressing cells increased Mo and PMN migration compared with media  
8 conditioned by control cells (**Fig.5F**), which was partially reversed after blocking IL6 and IL8  
9 with antibodies (**Fig.S6E**). In contrast, UBE2D3 down-regulation decreased Mo and PMN  
10 migration compared to control siRNA (siGL2) (**Fig.S6F**), and this effect was abolished by  
11 adding exogenously IL6 and IL8 (**Fig.S6G**). As expected, both cytokines were involved in Mo  
12 attraction, whereas only IL8 impacted PMN attraction (**Fig.S6E-G**), a result consistent with  
13 those presented in **Fig.2D**. In addition, Mo and PMN migration was reduced with media  
14 conditioned by UBE2D3 expressing RADH87 cells after MIB1 silencing, and this was reversed  
15 with exogenous IL6 and IL8 (**Fig.S6H**). Hence, we demonstrate that the signaling circuit  
16 involving IRE1/UBE2D3/MIB1 controls NF $\kappa$ B-mediated chemokines synthesis and  
17 inflammatory response in GB (**Fig.5G**).

18

### 19 **UBE2D3 promotes pro-tumoral inflammation *in vivo* and increases GB aggressiveness**

20 To assess the importance of IRE1/UBE2D3 signaling axis in GB, we used a syngeneic mouse  
21 model<sup>9</sup>. GL261 control and UBE2D3 overexpressing cells (**Fig.6A**) were orthotopically  
22 injected in immunocompetent C57BL/6 mice. Twenty-four days post-injection, tumors were  
23 resected, subjected to immunohistochemical analyses and the immune infiltrate was  
24 quantified. Interestingly, UBE2D3 GL261 cells produced larger tumors than their control  
25 counterparts (**Fig.6B**), although did not impact on mouse survival. This difference was not  
26 attributed to difference in proliferation rates *in vitro* (**Fig.S7A**), which suggests that the growth  
27 advantage of UBE2D3-overexpressing tumors might emerge from interaction with stroma

1 and/or tumor microenvironment. Accordingly, UBE2D3 tumors showed elevated NF $\kappa$ B  
2 expression (**Fig.6C**) and recruited significantly higher numbers of MM and PMN (**Fig.6D-E**),  
3 consistent with our *in vitro* findings. Furthermore, in UBE2D3-overexpressing cells, ccl2 and  
4 cxcl2 mRNA levels were increased, as well as other NF $\kappa$ B-dependent factors including g-csf,  
5 il1b and lif mRNA (**Fig.S7B**). Conditioned media from these cells also triggered Mo and PMN  
6 increased migration *in vitro* in a xenogeneic setting (**Fig.S7C**). Importantly, when ube2d3 was  
7 silenced in GL261 cells (**Fig.6F**), resulting tumors were smaller (**Fig.6G**), and mouse survival  
8 was extended compared to control cells (**Fig.6H**). Again, ube2d3 modulation did not influence  
9 GL261 proliferation *in vitro* (**Fig.S7D**), but affected mRNA expression of ccl2, cxcl2 as well as  
10 the factors under the control of NF $\kappa$ B activity i.e. g-csf, il1b and lif mRNA (**Fig.S7E**).  
11 Furthermore, conditioned media from GL261 shube2d3 cells were less efficient to promote  
12 Mo and PMN attraction *in vitro* (**Fig.S7F**). Since mice lack both *il8* and *il8 receptor (cxcr1)*  
13 genes, the PMN recruitment observed in our models could be due to cxcl1 and cxcl2, as  
14 previously reported in other mouse-bearing tumors infiltrated by PMN<sup>29,30</sup>. Using transcriptome  
15 data from two independent GB cohorts, GBMmark and TCGA-GBLGG, we observed a strong  
16 correlation between UBE2D3 expression and that of a large number of proinflammatory  
17 cytokines/chemokines (**Fig.S7G-H**). Intriguingly, high UBE2D3 expression was also  
18 associated with increased infiltration of monocytes, T cells and M2-polarized macrophages  
19 (**Fig.S7I-J**). Finally, to evaluate the clinical and prognostic relevance of UBE2D3 expression  
20 in GB, we investigated UBE2D3 expression in brain malignancies and showed that UBE2D3  
21 was markedly increased in GB specimens compared to low-grade gliomas (**Fig.6I**). Patients  
22 whose tumors displayed high UBE2D3 expression were found associated with poorer  
23 prognosis, consistent with the fact that high IRE1 activity status was also of poor prognosis  
24 (**Fig.6I**). Our findings unveil a novel IRE1-dependent mechanism promoting pro-tumoral  
25 inflammation that integrates UPR signaling and ubiquitin system. Here, we demonstrated that  
26 IRE1/UBE2D3 axis controls GB secretome composition through NF $\kappa$ B signaling activation  
27 (**Fig.6J**).



## 1 Discussion

2 In recent years, we have characterized the relevance of UPR signaling, in particular of the  
3 IRE1 arm, in GB<sup>7,8</sup> and found that characteristics of IRE1 signaling represent a predictive  
4 factor for GB aggressiveness<sup>10</sup>. As such, modulating ER stress signaling pathways represents  
5 an attractive therapeutic avenue for GB treatment aimed at either increasing ER stress to  
6 levels that trigger apoptosis or decreasing the adaptive UPR, leading to loss of cellular  
7 selective advantages or increased sensitivity to treatments, and subsequent death<sup>31</sup>. In  
8 addition to the intrinsic aggressiveness of GB cells, the brain tumor microenvironment, which  
9 contains among others endothelial and immune cells, is emerging as a crucial regulator of  
10 cancer progression. The most abundant immune cells in GB microenvironment are tumor-  
11 associated macrophages and microglial cells that might reach up to 30% of the tumor mass  
12 and are often linked to disease aggressiveness<sup>32,33</sup>. However, brain tumors are also infiltrated  
13 by other immune cells such as T, myeloid and plasmacytoid DCs, and neutrophils<sup>34</sup>.

14 In the present study, we demonstrated that IRE1 signaling in tumor cells plays a key  
15 role in regulating the GB microenvironment, by promoting myeloid recruitment to the tumors.  
16 We previously found that IRE1 signaling was involved in macrophages and microglial cells  
17 recruitment to the tumors<sup>10</sup> and that IRE1 controls proinflammatory chemokines expression<sup>5,35</sup>.  
18 Herein, we showed that pharmacological inhibition of IRE1 signaling decreased the extent of  
19 PMN infiltration into GB *in vivo* (**Fig.1**), which might be of clinical importance because elevated  
20 PMN recruitment correlated with poor outcome in GB patients. We also found that IRE1  
21 activation in tumor cells was correlated with higher expression of myeloid-attracting  
22 chemokines (**Fig.2**). Importantly, this occurred in the absence of ER stress induction,  
23 underlining the important function of constitutive IRE1 activity in GB cells, i.e. modulating  
24 tumor secretome composition.

25 Mechanistically, we showed that IRE1 tightly and oppositely controlled the expression  
26 of UBE2D3 in GB cells by engaging the XBP1s and RIDD branches (**Fig.3, 4**). This result  
27 might be indicative of a stress-dependent (nature, time, intensity) regulation of UBE2D3  
28 expression which could in turn find some spatial relevance in the whole tumor. We found that

1 activation of IRE1/UBE2D3 signaling axis was in part responsible for myeloid chemoattraction  
2 through NF $\kappa$ B activation (**Fig.5**). UBE2D3 is a E2 ubiquitin-conjugating enzyme that, together  
3 with E1 ubiquitin-activating enzyme and E3 ligase, mediates attachment of ubiquitin moieties  
4 to target proteins. This post-translational modification affects a broad range of biological  
5 processes, including protein quality control, trafficking, differentiation, cell division, signal  
6 transduction as well as inflammation<sup>36,37</sup>. UBE2D3 has been shown to control proteasomal  
7 degradation of, among others, p53<sup>38</sup>, cyclin D1<sup>39</sup>, p12 subunit of DNA polymerase  $\delta$ <sup>40</sup> and  
8 I $\kappa$ B $\alpha$ <sup>23,41</sup>. It was also reported to mediate RIG-I ubiquitination and thereby promote its  
9 activation upon viral infection to initiate a type I interferon-dependent innate immune  
10 response<sup>42</sup>. In this study, we further demonstrated the crucial role of UBE2D3 in  
11 immunity/inflammation regulation in pathological conditions, such as cancer. We found that  
12 UBE2D3 is overexpressed in GB compared to low-grade gliomas, and that its elevated  
13 expression correlates with a high abundance of proinflammatory molecules. We delineated a  
14 novel IRE1-dependent mechanism for NF $\kappa$ B activation, which involves upregulation of  
15 UBE2D3 leading to I $\kappa$ B degradation through, at least partially, the E3 ligase MIB1 activity  
16 (**Fig.5**), the subsequent nuclear translocation of NF $\kappa$ B and its downstream signaling  
17 activation. Hence, IRE1 controls proinflammatory chemokines synthesis, including CXCL2,  
18 IL6 and IL8. as demonstrated herein. Once secreted, they not only sustain the pro-tumoral  
19 inflammatory microenvironment but can also mobilize immune cells recruitment to tumor sites  
20 further promoting cancer progression. As such, we showed *in vivo* that UBE2D3-  
21 overexpressing tumors were bigger in size and were infiltrated by significantly higher numbers  
22 of immune cells, such as MM and PMN (**Fig.6**). Furthermore, reduction of UBE2D3 led to  
23 decreased tumor growth *in vivo* and to the subsequent increased mouse survival. However,  
24 our findings indicate that the aforementioned mechanism might be applicable to the infiltration  
25 by a large number of lymphocytes, highlighting the importance of understanding the  
26 IRE1/UBE2D3 axis in other cancer models, particularly in 'immune hot' tumors. Recent studies  
27 using single-cell technologies reveal a large range of transcriptome phenotypes from myeloid

1 cells including both MDM and MG cells in GB<sup>13-15</sup>. The multidimensional heterogeneity of  
2 these myeloid populations (i.e. resting, repressed MG, primed MDM) renders complex their  
3 identification and studies<sup>43,44</sup>. Notably, IRE1 is involved in macrophage polarization in  
4 melanoma<sup>45</sup>. Whether and how IRE1 could be involved in controlling MDM/MG cell states  
5 and/or functions has to be further studied. Furthermore, the cross-talk between myeloid cells  
6 might determine GB cell fate and nature i.e., pro-neural to mesenchymal transition<sup>46</sup>.

7 In the context of those findings, immunotherapy which has clearly proven its efficacy  
8 as an anti-cancer treatment<sup>47,48</sup>, has so far led to disappointing results in GB, likely because  
9 of the powerful immunosuppressive features of those tumors<sup>48</sup>. Neutrophil-activating therapy  
10 is emerging as a powerful anti-cancer immunotherapeutic approach in mouse breast, colon  
11 and melanoma models<sup>49</sup>. Specific PMN activators including TNF, agonistic anti-CD40 and  
12 anti-tumor antibodies allow the PMN recruitment at metastatic sites and activate PMN-  
13 mediated antibody-dependent cytotoxicity against tumor cells. The current work implies that  
14 targeting IRE1 signaling might impede GB aggressiveness by reducing tumor cell invasion  
15 and angiogenesis<sup>8,10</sup>, but also by attenuating pro-tumoral inflammation and immunity. This  
16 study opens a new avenue for therapeutic approaches to improve the efficacy of current and  
17 future immunotherapies.

18

1 **Funding**

2 This work was funded by grants from la Ligue Contre le Cancer, from INSERM, from Région  
3 Bretagne and from INCR to AT; from INSERM (IRP 2020 Tupric), Institut National du Cancer  
4 (INCa; PLBio 2017, 2019, 2020), Région Bretagne, Rennes Métropole, Fondation pour la  
5 recherche Médicale (FRM; équipe labellisée 2018 and DEQ20180339169), EU H2020 MSCA  
6 ITN-675448 (TRAINERS), la Ligue Contre le Cancer Comités d'Ille-et-Vilaine, des Côtes  
7 d'Armor et du Morbihan and MSCA RISE-734749 (INSPIRED) to EC; ELIXIR-GR "The  
8 Hellenic infrastructure for biological data management and analysis" (MIS: 5002780),  
9 "Reinforcement of the Research and Innovation Infrastructure", and the Operational  
10 Programme "Competitiveness, Entrepreneurship and Innovation" (NSRF 2014-2020) co-  
11 financed by Greece and the European Union (European Regional Development Fund) to AC.

12

13 **Data Availability Statement**

14 Materials described in the manuscript, including all relevant raw data, are freely available to  
15 any researcher wishing to use them for non-commercial purposes, without breaching  
16 participant confidentiality.

17

## 1 References

- 2 1. Chevet E, Hetz C, Samali A. Endoplasmic Reticulum Stress-Activated Cell  
3 Reprogramming in Oncogenesis. *Cancer discovery*. 2015;5(6):586-597. doi:10.1158/2159-  
4 8290.CD-14-1490
- 5 2. Almanza A, Carlesso A, Chintha C, et al. Endoplasmic reticulum stress signalling -  
6 from basic mechanisms to clinical applications. *The FEBS journal*. Published online July 20,  
7 2018. doi:10.1111/febs.14608
- 8 3. Maurel M, Chevet E, Tavernier J, Gerlo S. Getting RIDD of RNA: IRE1 in cell fate  
9 regulation. *Trends in biochemical sciences*. 2014;39(5):245-254.  
10 doi:10.1016/j.tibs.2014.02.008 10.1016/j.tibs.2014.02.008. Epub 2014 Mar 20.
- 11 4. Urra H, Dufey E, Avril T, Chevet E, Hetz C. Endoplasmic Reticulum Stress and the  
12 Hallmarks of Cancer. *Trends Cancer*. 2016;2(5):252-262. doi:10.1016/j.trecan.2016.03.007
- 13 5. Logue SE, McGrath EP, Cleary P, et al. Inhibition of IRE1 RNase activity modulates  
14 the tumor cell secretome and enhances response to chemotherapy. *Nature communications*.  
15 2018;9(1):3267. doi:10.1038/s41467-018-05763-8
- 16 6. Obacz J, Avril T, Rubio-Patiño C, et al. Regulation of tumor-stroma interactions by  
17 the unfolded protein response. *FEBS J*. 2019;286(2):279-296. doi:10.1111/febs.14359
- 18 7. Dejeans N, Pluquet O, Lhomond S, et al. Autocrine control of glioma cells adhesion  
19 and migration through IRE1alpha-mediated cleavage of SPARC mRNA. *Journal of cell*  
20 *science*. 2012;125(Pt 18):4278-4287. doi:jcs.099291 [pii]10.1242/jcs.099291  
21 10.1242/jcs.099291. Epub 2012 Jun 20.
- 22 8. Auf G, Jabouille A, Guerit S, et al. Inositol-requiring enzyme 1alpha is a key  
23 regulator of angiogenesis and invasion in malignant glioma. *Proceedings of the National*  
24 *Academy of Sciences of the United States of America*. 2010;107(35):15553-15558.  
25 doi:10.1073/pnas.0914072107
- 26 9. Le Reste PJ, Pineau R, Voutetakis K, et al. Local intracerebral inhibition of IRE1 by  
27 MKC8866 sensitizes glioblastoma to irradiation/chemotherapy in vivo. *Cancer Lett*.  
28 2020;494:73-83. doi:10.1016/j.canlet.2020.08.028
- 29 10. Lhomond S, Avril T, Dejeans N, et al. Dual IRE1 RNase functions dictate  
30 glioblastoma development. *EMBO molecular medicine*. Published online January 8, 2018.  
31 doi:10.15252/emmm.201707929
- 32 11. Hu P, Han Z, Couvillon AD, Kaufman RJ, Exton JH. Autocrine tumor necrosis factor  
33 alpha links endoplasmic reticulum stress to the membrane death receptor pathway through  
34 IRE1alpha-mediated NF-kappaB activation and down-regulation of TRAF2 expression.  
35 *Molecular and cellular biology*. 2006;26(8):3071-3084.
- 36 12. Avril T, Vauleon E, Hamlat A, et al. Human glioblastoma stem-like cells are more  
37 sensitive to allogeneic NK and T cell-mediated killing compared with serum-cultured  
38 glioblastoma cells. *Brain pathology*. 2012;22(2):159-174. doi:10.1111/j.1750-  
39 3639.2011.00515.x
- 40 13. Yin W, Ping YF, Li F, et al. A map of the spatial distribution and tumour-associated  
41 macrophage states in glioblastoma and grade-4 IDH-mutant astrocytoma. *J Pathol*. Published  
42 online June 20, 2022. doi:10.1002/path.5984
- 43 14. Bowman RL, Klemm F, Akkari L, et al. Macrophage Ontogeny Underlies Differences  
44 in Tumor-Specific Education in Brain Malignancies. *Cell Rep*. 2016;17(9):2445-2459.  
45 doi:10.1016/j.celrep.2016.10.052
- 46 15. Cui X, Wang Q, Zhou J, et al. Single-Cell Transcriptomics of Glioblastoma Reveals a  
47 Unique Tumor Microenvironment and Potential Immunotherapeutic Target Against Tumor-  
48 Associated Macrophage. *Front Oncol*. 2021;11:710695. doi:10.3389/fonc.2021.710695
- 49 16. Badie B, Schartner JM. Flow cytometric characterization of tumor-associated

- 1 macrophages in experimental gliomas. *Neurosurgery*. 2000;46(4):957-961; discussion 961-2.
- 2 17. Pelizzari-Raymundo D, Doultsinos D, Pineau R, et al. A novel IRE1 kinase inhibitor
- 3 for adjuvant glioblastoma treatment. *iScience*. 2023;26(5):106687.
- 4 doi:10.1016/j.isci.2023.106687
- 5 18. Chevet E, Doultsinos D, Eriksson L a, et al. Compounds Containing a Hydroxyphenyl
- 6 Moiety and Their Use. 2023;(EP22305014A·2022-01-07).
- 7 19. Powell DR, Huttenlocher A. Neutrophils in the Tumor Microenvironment. *Trends in*
- 8 *immunology*. 2016;37(1):41-52. doi:10.1016/j.it.2015.11.008
- 9 20. Guedes JR, Lao T, Cardoso AL, El Khoury J. Roles of Microglial and Monocyte
- 10 Chemokines and Their Receptors in Regulating Alzheimer's Disease-Associated Amyloid-
- 11 beta and Tau Pathologies. *Front Neurol*. 2018;9:549. doi:10.3389/fneur.2018.00549
- 12 21. Chen X, Iliopoulos D, Zhang Q, et al. XBP1 promotes triple-negative breast cancer by
- 13 controlling the HIF1alpha pathway. *Nature*. 2014;508(7494):103-107.
- 14 doi:10.1038/nature13119
- 15 22. Richmond A. Nf-kappa B, chemokine gene transcription and tumour growth. *Nat Rev*
- 16 *Immunol*. 2002;2(9):664-674. doi:10.1038/nri887
- 17 23. Yaron A, Hatzubai A, Davis M, et al. Identification of the receptor component of the
- 18 IkkappaBalpha-ubiquitin ligase. *Nature*. 1998;396(6711):590-594. doi:10.1038/25159
- 19 24. Gonen H, Bercovich B, Orian A, et al. Identification of the ubiquitin carrier proteins,
- 20 E2s, involved in signal-induced conjugation and subsequent degradation of IkkappaBalpha.
- 21 *The Journal of biological chemistry*. 1999;274(21):14823-14830.
- 22 doi:10.1074/jbc.274.21.14823
- 23 25. Nadav E, Shmueli A, Barr H, Gonen H, Ciechanover A, Reiss Y. A novel mammalian
- 24 endoplasmic reticulum ubiquitin ligase homologous to the yeast Hrd1. *Biochem Biophys Res*
- 25 *Commun*. 2003;303(1):91-97. doi:10.1016/s0006-291x(03)00279-1
- 26 26. Gao B, Lee SM, Chen A, et al. Synoviolin promotes IRE1 ubiquitination and
- 27 degradation in synovial fibroblasts from mice with collagen-induced arthritis. *EMBO Rep*.
- 28 2008;9(5):480-485. doi:10.1038/embor.2008.37
- 29 27. Liu LJ, Liu TT, Ran Y, et al. The E3 ubiquitin ligase MIB1 negatively regulates basal
- 30 IkkappaBalpha level and modulates NF-kappaB activation. *Cell Res*. 2012;22(3):603-606.
- 31 doi:10.1038/cr.2011.199
- 32 28. van Wijk SJ, de Vries SJ, Kemmeren P, et al. A comprehensive framework of E2-
- 33 RING E3 interactions of the human ubiquitin-proteasome system. *Molecular systems biology*.
- 34 2009;5:295. doi:10.1038/msb.2009.55
- 35 29. Jablonska J, Wu CF, Andzinski L, Leschner S, Weiss S. CXCR2-mediated tumor-
- 36 associated neutrophil recruitment is regulated by IFN-β. *International Journal of Cancer*.
- 37 2014;134(6):1346-1358. doi:10.1002/ijc.28551
- 38 30. Gershkovitz M, Fainsod-Levi T, Zelter T, Sionov RV, Granot Z. TRPM2 modulates
- 39 neutrophil attraction to murine tumor cells by regulating CXCL2 expression. *Cancer*
- 40 *Immunol Immunother*. 2019;68(1):33-43. doi:10.1007/s00262-018-2249-2
- 41 31. Obacz J, Avril T, Le Reste PJ, et al. Endoplasmic reticulum proteostasis in
- 42 glioblastoma-From molecular mechanisms to therapeutic perspectives. *Sci Signal*.
- 43 2017;10(470):eaal2323. doi:10.1126/scisignal.aal2323
- 44 32. Hambardzumyan D, Gutmann DH, Kettenmann H. The role of microglia and
- 45 macrophages in glioma maintenance and progression. *Nature neuroscience*. 2016;19(1):20-
- 46 27. doi:10.1038/nn.4185
- 47 33. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in
- 48 tumour progression: implications for new anticancer therapies. *The Journal of pathology*.
- 49 2002;196(3):254-265. doi:10.1002/path.1027
- 50 34. Quail DF, Joyce JA. The Microenvironmental Landscape of Brain Tumors. *Cancer*

- 1 *cell*. 2017;31(3):326-341. doi:10.1016/j.ccell.2017.02.009
- 2 35. Pluquet O, Dejeans N, Bouchecareilh M, et al. Posttranscriptional regulation of PER1  
3 underlies the oncogenic function of IRE $\alpha$ . *Cancer research*. 2013;73(15):4732-4743.  
4 doi:10.1158/0008-5472.CAN-12-3989
- 5 36. Mukhopadhyay D, Riezman H. Proteasome-independent functions of ubiquitin in  
6 endocytosis and signaling. *Science*. 2007;315(5809):201-205. doi:10.1126/science.1127085
- 7 37. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway:  
8 destruction for the sake of construction. *Physiological reviews*. 2002;82(2):373-428.  
9 doi:10.1152/physrev.00027.2001
- 10 38. Saville MK, Sparks A, Xirodimas DP, et al. Regulation of p53 by the ubiquitin-  
11 conjugating enzymes UbcH5B/C in vivo. *The Journal of biological chemistry*.  
12 2004;279(40):42169-42181. doi:10.1074/jbc.M403362200
- 13 39. Hattori H, Zhang X, Jia Y, et al. RNAi screen identifies UBE2D3 as a mediator of all-  
14 trans retinoic acid-induced cell growth arrest in human acute promyelocytic NB4 cells.  
15 *Blood*. 2007;110(2):640-650. doi:10.1182/blood-2006-11-059048
- 16 40. Zhang S, Zhou Y, Sarkeshik A, et al. Identification of RNF8 as a ubiquitin ligase  
17 involved in targeting the p12 subunit of DNA polymerase delta for degradation in response to  
18 DNA damage. *The Journal of biological chemistry*. 2013;288(5):2941-2950.  
19 doi:10.1074/jbc.M112.423392
- 20 41. Wu K, Kovacev J, Pan ZQ. Priming and extending: a UbcH5/Cdc34 E2 handoff  
21 mechanism for polyubiquitination on a SCF substrate. *Molecular cell*. 2010;37(6):784-796.  
22 doi:10.1016/j.molcel.2010.02.025
- 23 42. Shi Y, Yuan B, Zhu W, et al. Ube2D3 and Ube2N are essential for RIG-I-mediated  
24 MAVS aggregation in antiviral innate immunity. *Nature communications*. 2017;8:15138.  
25 doi:10.1038/ncomms15138
- 26 43. Yeo AT, Rawal S, Delcuze B, et al. Single-cell RNA sequencing reveals evolution of  
27 immune landscape during glioblastoma progression. *Nat Immunol*. 2022;23(6):971-984.  
28 doi:10.1038/s41590-022-01215-0
- 29 44. Arrieta VA, Najem H, Petrosyan E, et al. The Eclectic Nature of Glioma-Infiltrating  
30 Macrophages and Microglia. *Int J Mol Sci*. 2021;22(24):13382. doi:10.3390/ijms222413382
- 31 45. Batista A, Rodvold JJ, Xian S, et al. IRE1 $\alpha$  regulates macrophage polarization, PD-L1  
32 expression, and tumor survival. *PLOS Biology*. 2020;18(6):e3000687.  
33 doi:10.1371/journal.pbio.3000687
- 34 46. Chen Z, Soni N, Pinero G, et al. Monocyte depletion enhances neutrophil influx and  
35 proneural to mesenchymal transition in glioblastoma. *Nat Commun*. 2023;14(1):1839.  
36 doi:10.1038/s41467-023-37361-8
- 37 47. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. *Science*.  
38 2018;359(6382):1350-1355. doi:10.1126/science.aar4060
- 39 48. Lim M, Xia Y, Bettgowda C, Weller M. Current state of immunotherapy for  
40 glioblastoma. *Nature reviews Clinical oncology*. 2018;15(7):422-442. doi:10.1038/s41571-  
41 018-0003-5
- 42 49. Linde IL, Prestwood TR, Qiu J, et al. Neutrophil-activating therapy for the treatment  
43 of cancer. *Cancer Cell*. 2023;41(2):356-372.e10. doi:10.1016/j.ccell.2023.01.002
- 44

## 1 **Figure Legends**

### 2 **Figure 1. Impact of IRE1 on myeloid recruitment to GB *in vitro* and *in vivo*.**

3 **(A)** Hierarchical clustering of TCGA GB patients based on high/low IRE1 activity was  
4 confronted to immune markers for MM, MDM, MG, PMN and T cells. UP (n) and *p* values  
5 denote the proportion of signature genes that were found up-regulated between the groups  
6 (n=number of genes) and the estimated two-sided directional *p*-value of test, respectively. **(B)**  
7 Total immune infiltrate of GB (n=82) and grade II/III (n=8/14) glioma analyzed by flow  
8 cytometry using anti-CD45 antibodies. (\*\*\*) : *p*<0.001 according to unpaired t-test compared  
9 to GB. **(C)** Percentage of specific GB infiltrated leukocytes populations analyzed by flow  
10 cytometry using anti-CD45/CD11b antibodies. Tumors were classified according to IRE1  
11 activity (high/blue in red/blue) (n=31). **(D)** Total immune infiltrate of GB classified according to  
12 IRE1 activity (high/low in red/blue, n=14/7) and analyzed by flow cytometry using anti-CD45  
13 antibodies. Tumors were classified using transcriptome analysis according to IRE1 signature.  
14 (\*\*\*) : *p*<0.001 according to unpaired t-test compared to tumors with high IRE1 activity. **(E)**  
15 Deeper characterization of immune subtypes was performed combining specific markers i.e.  
16 MM markers CD14, CD64 (for MDM/MMG), CD163 (for MDM), PMN markers CD15 and  
17 CD66B, and T marker CD3. Tumors were classified according to IRE1 activity (high/low,  
18 n=10/5). ns: not significant, (\*) : *p*<0.05 and (\*\*): *p*<0.01 according to unpaired t-test compared  
19 to tumors with high IRE1 activity. **(F, G)** Freshly isolated Mo and PMN were placed in Boyden  
20 chambers towards fresh medium (-), conditioned media from U87 (par.), U87 DN (DN),  
21 RADH87 (par.), RADH87 cells overexpressing IRE1 (WT) or Q780\* (Q\*) (n=3, mean±SD). ns:  
22 not significant, (\*) : *p*<0.05, (\*\*): *p*<0.01, (\*\*\*\*): *p*<0.0001 according to unpaired t-test compared  
23 to media from parental. **(H)** Representative immunohistological analysis of myeloid infiltration  
24 in GB resected from GL261 and CT2A-implanted mice treated with plug with IRE1 inhibitor  
25 MKC8866 (for GL261) and B2-1 (for CT2A), respectively. MM and PMN were detected with  
26 anti-IBA1 and anti-Ly6G antibodies, respectively. Scale bar 100 μm. **(I)** Semi-quantitative  
27 analysis of IBA1 and Ly6G staining from (H). *p* values from unpaired t-test compared to CTR;  
28 ns: not significant.



1

2 **Figure 2. IRE1-mediated synthesis of myeloid-attracting chemokines.**

3 **(A)** Hierarchical clustering of TCGA GB patients based on high/low IRE1 activity (n=264/275)  
4 confronted to chemokines expression involved in myeloid chemoattraction. *p* values obtained  
5 using unpaired t-test comparing IRE1 high versus low tumors. **(B)** Chemokines mRNA  
6 expression in TCGA GB tumors with high/low (red/blue) MM and PMN infiltration determined  
7 according to CD14 or CD15 levels, respectively. CD14/CD15 high/low groups were  
8 determined using the median of the marker mRNA expression as cut-off (high/low n=263/263).  
9 *p* values according to unpaired t-test comparing chemokines mRNA expression between  
10 CD14/CD15 high versus low tumors. **(C)** Correlation between chemokines secretion and Mo/  
11 PMN migration towards tumor conditioned media from different GB lines (n= 7 and 20 for Mo  
12 and PMN respectively). R square and *p* values of the slopes were calculated using Pearson  
13 correlation coefficient analysis between chemokines secretion and myeloid attraction; ns: not  
14 significant and (\*): *p*<0.05. **(D)** Myeloid migration assay was performed as described in **Fig.1**,  
15 in the presence of SB225002, a CXCR2 antagonist (n=3 and 4 for Mo and PMN respectively,  
16 mean±SD). ns: not significant and (\*\*): *p*<0.01 according to unpaired t-test compared to  
17 DMSO. **(E)** Quantification of myeloid-attracting chemokines mRNA abundance using RT-  
18 qPCR in parental U87 and RADH87 cells (-) transiently overexpressing TRAP-Nck (TRAP),  
19 IRE1-Nck (DN), IRE1-Q780\* (Q) (n=4). *p* values according to an ANOVA test comparing the  
20 four conditions. **(F)** Quantification of chemokines mRNA expression using RT-qPCR in  
21 parental U87 (par.), U87 DN (stably overexpressing IRE1-Nck), parental RADH87 or RADH87  
22 cells stably overexpressing wild-type (WT) or Q780\* (Q\*) IRE1 (n=at least 6, mean±SD). ns:  
23 not significant, (\*\*): *p*<0.01, (\*\*\*): *p*<0.001, (\*\*\*\*): *p*<0.0001 according to unpaired t-test  
24 compared to parental.

25

26 **Figure 3. IRE1/XBP1-dependent regulation of UBE2D3.**

27 **(A)** IRE1, XBP1s and RIDD signatures were confronted to NFκB signaling gene signature  
28 using the TCGA GB dataset (IRE1 high/low n=264/275; XBP1s high/low n=261/210; and RIDD

1 high/low n=285/249). *p* values obtained with unpaired t-test comparing IRE1, XBP1s and  
2 RIDD high versus low tumors. **(B)** Venn diagram of the intersection of XBP1s target genes  
3 identified by ChIPseq<sup>21</sup> with RIDD targets<sup>10</sup>. **(C)** Association of NFκB signature with NCSTN,  
4 UBE2D3 and UFM1 low/high GB from TCGA. NCSTN, UBE2D3 and UFM1 high/low groups  
5 were determined using the median of the mRNA expression as cut-off (high/low n=263/263).  
6 *p* values obtained from unpaired t-test comparing NCSTN, UBE2D3 and UFM1 high versus  
7 low tumors. **(D)** UBE2D3 mRNA expression in TCGA GB categorized according to their IRE1,  
8 XBP1s and RIDD signatures (IRE1 high/low n=258/265; XBP1s high/low n=261/210; and  
9 RIDD high/low n=252/258). *p* values obtained with unpaired t-test comparing IRE1, XBP1s  
10 and RIDD high versus low tumors. **(E)** UBE2D3 mRNA expression in XBP1s low/high TCGA  
11 GB (RNAseq dataset; high/low n=80/86). *p* value obtained from unpaired t-test comparing  
12 XBP1s high versus low tumors. **(F)** Quantitation of UBE2D3 mRNA expression using RT-  
13 qPCR in U87 and RADH87 cells silenced for XBP1 (n=7 and 4 respectively for U87 and  
14 RADH87). ns: not significant according to unpaired t-test compared to control. **(G)** Western  
15 blot analysis of UBE2D3 in parental (NT), control (siCTR) and XBP1-silenced (siXBP1) U87  
16 and RADH87 cells. Actin (ACT) was used as loading control. Data are representative of three  
17 biological replicates (see **Fig.S4F**). **(H)** Quantification of UBE2D3 mRNA expression by RT-  
18 qPCR in cells with active (parental U87 and RADH87 (par)) and inactive IRE1 signaling (U87  
19 DN and RADH87 Q780\*) (n=4, mean±SD). (\*): *p*<0.05 according to unpaired t-test compared  
20 to parental. **(I)** Quantitation of UBE2D3 expression with RT-qPCR in U87 DN and RADH87 Q\*  
21 cells and transfected with XBP1s (n=3). (\*): *p*<0.05, (\*\*): *p*<0.001 according to unpaired t-test  
22 comparing CTR to XBP1s conditions. **(J)** Putative XBP1s binding sites (green) on human  
23 UBE2D3 promoter regions analyzed with MatInspector and TFBIND. **(K-L)** Gel shift assays  
24 performed on 4 putative XBP1s binding sites using U87 nuclear extracts after XBP1s  
25 overexpression (K). Validation of putative binding sites *h1*, *h2* and *h3* using gradual amounts  
26 of unlabeled probes used in competition assay (L).

27

28

1 **Figure 4. IRE1/RIDD-dependent regulation of UBE2D3.**

2 **(A)** Western blot analysis of UBE2D3 in U87 cells treated with MKC8866 (MKC) under basal  
3 or ER stress condition using thapsigargin (Tg, 50 nM). *p* value obtained using an ANOVA test.

4 **(B)** Western blot analysis of IRE1 and UBE2D3 in U87 cells silenced for UBE2D3 and UBE2D3  
5 overexpressing RADH87 cells under basal or ER stress condition using tunicamycin (Tm, 1  
6 µg/mL). **(C)** Western blot analysis of IRE1 and UBE2D3 in UBE2D3 overexpressing U87 cells  
7 silenced for SYVN1 under basal or ER stress condition using Tm. **(D)** Schematic  
8 representation of IRE1 regulation of UBE2D3 expression with a retro-control loop involving  
9 SYVN1.

10

11 **Figure 5. Impact of UBE2D3 on NFκB activation and chemokines synthesis.**

12 **(A-B)** Western blot analysis of NFκB, phospho-NFκB, IκB and phospho-IκB in control (EV)  
13 and transiently (U87) or stably (RADH87) UBE2D3 overexpressing cells (A); and after MIB1  
14 down-regulation (siMIB1) (B). UBE2D3 over-expression was checked. **(C)** Chemokines  
15 mRNA expression in TCGA GB specimens categorized according to UBE2D3 expression.  
16 UBE2D3 high/low (red/blue, n=263/263) groups were determined using the median of the  
17 mRNA expression as cut-off. *p* values obtained from unpaired t-test comparing UBE2D3 high  
18 versus low tumors. **(D)** Quantification of chemokines expression using RT-qPCR in control  
19 (CTR) U87, parental (par.) RADH87, transient U87 and stable RADH87 cells overexpressing  
20 UBE2D3 (n=3, mean±SD). (\*): *p*<0.05, (\*\*): *p*<0.01, (\*\*\*): *p*<0.001, (\*\*\*\*): *p*<0.0001 according  
21 to unpaired t-test compared to control. **(E)** Quantification of chemokines expression using RT-  
22 qPCR in U87 (EV) or UBE2D3 overexpressing cells treated with 5 µM JSH-23 (n=3,  
23 mean±SD). (\*): *p*<0.05, (\*\*): *p*<0.01, (\*\*\*\*): *p*<0.0001 according to unpaired t-test compared  
24 to control. **(F)** Myeloid migration (Mo and PMN) was performed as described in **Fig.1**, towards  
25 media conditioned by U87 control (CTR) and UBE2D3 overexpressing cells (n=3, mean±SD).  
26 (\*): *p*<0.05 and (\*\*\*): *p*<0.001 according to unpaired t-test compared to control. **(G)** Schematic  
27 representation of UBE2D3 impact on inflammatory response in GB.

28

1 **Figure 6. Impact of UBE2D3 overexpression on inflammation *in vivo*.**  
2 **(A)** UBE2D3 protein overexpression in five UBE2D3 transfected GL261 stable lines. UBE2D3  
3 protein level was measured with anti-Flag antibodies. **(B)** Left panel: brain sections from mice  
4 injected with GL261 control (CTR) or GL261\_UBE2D3 cells analyzed for vimentin expression.  
5 Scale bar 1 mm. Right panel: tumor volume in control and UBE2D3 overexpressing (oe) group  
6 (n=3 and 10, mean±SD). ns: not significant according to unpaired t-test compared to control.  
7 **(C-E)** Left panel: Representative immunohistological NFκB expression (n=7/15, mean±SD)  
8 (C), macrophages/microglia infiltration (n=18, mean±SD) (D) and neutrophils infiltration (n=24,  
9 mean±SD) (E) in GL261 control or GL261\_UBE2D3 tumors detected by anti-NFκB, anti-IBA1  
10 and anti-Ly6G antibodies, respectively. Scale bar 100 μm. Right panel: semi-quantitative  
11 analyses of NFκB (C), IBA1 (D) and Ly6G staining (E) in control and GL261\_UBE2D3 tumors.  
12 (\*): $p<0.05$ , (\*\*): $p<0.01$  according to unpaired t-test compared to control. **(F)** UBE2D3 protein  
13 silencing in two GL261 stable lines transfected with shube2d3 construct. UBE2D3 protein level  
14 was measured using anti-ube2d3 antibodies. **(G)** Left panel: brain sections from mice injected  
15 with GL261 shCTR or shube2d3 GL261 cells analyzed for vimentin expression. Scale bar 1  
16 mm. Right panel: tumor volume in shCTR and shube2d3 group (n=4, mean±SD). (\*):  $p<0.05$   
17 according to unpaired t-test comparing to control. **(H)** Mouse survival of mouse bearing  
18 parental, shCTR and shube2d3 GL261 cells. (\*\*\*):  $p<0.001$  according to unpaired t-test  
19 comparing to parental. **(I)** UBE2D3 expression in LGG and GB (mean;  $p$  value according to  
20 unpaired t-test compared to GB); and its impact on patients' survival. **(J)** Schematic  
21 representation of IRE1/UBE2D3 axis in the regulation of pro-tumoral inflammation.

22  
23  
24  
25  
26  
27

Figure 1





Figure 2



1

**Figure 3**






Figure 4





**Figure 5**



1

**Figure 6**

